Cargando…
Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment)
BACKGROUND: Management of metastatic melanoma is changing rapidly following the introduction of innovative effective therapies, with consequences for the allocation of healthcare resources. The objective of this study was to assess hospitalisation costs of metastatic melanoma in France from 2011 to...
Autores principales: | Fernandes, Jérôme, Bregman, Bruno, Combemale, Patrick, Amaz, Camille, de Léotoing, Lucie, Vainchtock, Alexandre, Gaudin, Anne-Françoise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549336/ https://www.ncbi.nlm.nih.gov/pubmed/28789648 http://dx.doi.org/10.1186/s12913-017-2472-0 |
Ejemplares similares
-
Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020) -
Hospital burden of pulmonary arterial hypertension in France
por: Bergot, Emmanuel, et al.
Publicado: (2019) -
UniversitätsSpital Zürich: 80 years of neurosurgical patient care in Switzerland
por: Stienen, Martin N., et al.
Publicado: (2017) -
Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis
por: Girard, Nicolas, et al.
Publicado: (2018) -
Hospital costs impact of post ischemic stroke dysphagia: Database analyses of hospital discharges in France and Switzerland
por: Muehlemann, Natalia, et al.
Publicado: (2019)